|
1
|
Zucman J, Delattre O, Desmaze C, Epstein
AL, Stenman G, Speleman F, Fletchers CD, Aurias A and Thomas G: EWS
and ATF-1 gene fusion induced by t(12;22) translocation in
malignant melanoma of soft parts. Nat Genet. 4:341–345.
1993.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Thway K and Fisher C: Tumors with
EWSR1-CREB1 and EWSR1-ATF1 fusions: The current status. Am J Surg
Pathol. 36:e1–e11. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Enzinger FM: Clear-cell sarcoma of tendons
and aponeuroses. An analysis of 21 cases. Cancer. 18:1163–1174.
1965.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chung EB and Enzinger FM: Malignant
melanoma of soft parts. A reassessment of clear cell sarcoma. Am J
Surg Pathol. 7:405–413. 1983.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ibrahim RM, Steenstrup Jensen S and Juel
J: Clear cell sarcoma-A review. J Orthop. 15:963–966.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Andreou D and Tunn PU: Sentinel node
biopsy in soft tissue sarcoma. Recent Results Cancer Res.
179:25–36. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Andreou D, Boldt H, Werner M, Hamann C,
Pink D and Tunn PU: Sentinel node biopsy in soft tissue sarcoma
subtypes with a high propensity for regional lymphatic
spread-results of a large prospective trial. Ann Oncol.
24:1400–1405. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mavrogenis A, Bianchi G, Stavropoulos N,
Papagelopoulos P and Ruggieri P: Clinicopathological features,
diagnosis and treatment of clear cell sarcoma/melanoma of soft
parts. Hippokratia. 17:298–302. 2013.PubMed/NCBI
|
|
9
|
Egawa Y, Saigo C, Kito Y, Moriki T and
Takeuchi T: Therapeutic potential of CPI-613 for targeting tumorous
mitochondrial energy metabolism and inhibiting autophagy in clear
cell sarcoma. PLoS One. 13(e0198940)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kawashima K, Saigo C, Kito Y, Hanamatsu Y,
Egawa Y and Takeuchi T: CD151 confers metastatic potential to clear
cell sarcoma of the soft tissue in animal model. Oncol Lett.
17:4811–4818. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
MacDougall JR, Croy BA, Chapeau C and
Clark DA: Demonstration of a splenic cytotoxic effector cell in
mice of genotype SCID/SCID.BG/BG. Cell Immunol. 130:106–117.
1990.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Budzynski W and Radzikowski C: Cytotoxic
cells in immunodeficient athymic mice. Immunopharmacol
Immunotoxicol. 16:319–346. 1994.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sonobe H, Furihata M, Iwata J, Ohtsuki Y,
Mizobuchi H, Yamamoto H and Kumano O: Establishment and
characterization of a new human clear-cell sarcoma cell-line,
HS-MM. J Pathol. 169:317–322. 1993.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sonobe H, Takeuchi T, Taguchi T, Shimizu
K, Iwata J, Furihata M and Ohtsuki Y: Further characterization of
the human clear cell sarcoma cell line HS-MM demonstrating a
specific t(12;22)(q13;q12) translocation and hybrid EWSR1/ATF-1
transcript. J Pahol. 187:594–597. 1999.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Takeuchi T, Adachi Y and Nagayama T: A
WWOX-binding molecule, transmembrane protein 207, is related to the
invasiveness of gastric signet-ring cell carcinoma. Carcinogenesis.
33:548–554. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Asano Y, Takeuchi T, Okubo H, Saigo C,
Kito Y, Iwata Y, Futamura M and Yoshida K: Nuclear localization of
LDL receptor-related protein 1B in mammary gland carcinogenesis. J
Mol Med (Berl). 97:257–268. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
R Core Team: R: A language and environment
for statistical computing. R Foundation for Statistical Computing,
Vienna, 2014.
|
|
20
|
Chan CJ, Martinet L, Gilfillan S,
Souza-Fonseca-Guimaraes F, Chow MT, Town L, Ritchie DS, Colonna M,
Andrews DM and Smyth MJ: The receptors CD96 and CD226 oppose each
other in the regulation of natural killer cell functions. Nat
Immunol. 15:431–438. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Ochoa MC, Minute L, Rodriguez I, Garasa S,
Perez-Ruiz E, Inogés S, Melero I and Berraondo P:
Antibody-dependent cell cytotoxicity: Immunotherapy strategies
enhancing effector NK cells. Immunol Cell Biol. 95:347–355.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Faltas B: Cornering metastases:
Therapeutic targeting of circulating tumor cells and stem cells.
Front Oncol. 2(68)2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Narasimhan PB, Eggert T, Zhu YP,
Marcovecchio P, Meyer MA, Wu R and Hedrick CC: Patrolling monocytes
control NK cell expression of activating and stimulatory receptors
to curtail lung metastases. J Immunol. 204:192–198. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Bi J and Tian Z: NK cell dysfunction and
checkpoint immunotherapy. Front Immunol. 10(1999)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
López-Soto A, Gonzalez S, Smyth MJ and
Galluzzi L: Control of metastasis by NK cells. Cancer Cell.
32:135–154. 2017.PubMed/NCBI View Article : Google Scholar
|
